Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 3, 2007

Scientists Provide Results for Treating Chronic Lung Disease in Premature Infants

  • Researchers found that the activity of transforming growth factor-beta (TGF-beta) is elevated in the lungs of a mice model of bronchopulmonary dysplasia (BDP). Additionally, treatment with an antibody to TGF-beta decreased the growth factor’s activity and improved lung development.

    To test TGF-beta affect on BDP, a group of pregnant mice received injections of either an antibody against TGF-beta or a control substance a few days before giving birth. Their offspring were housed in either normal air or 85% oxygen, a concentration known to cause BPD in mice, for 10 days after birth.

    The investigators from Massachusetts General Hospital and Genzyme saw that the newborn mice exposed to high oxygen levels without the neutralizing antibody treatment had elevated TGF-beta activity. Their alveoli were also incompletely developed, a deficit typically seen in BPD.

    The mice that received the TGF-beta-neutralizing antibody showed significantly lower levels of growth factor activity and more normal lung development. Moreover, the improved lung development of these mice was also associated with improved body growth, at a rate of which was virtually identical to that of the animals in normal air.

    This study will appear in the American Journal of Physiology—Lung Cellular and Molecular Physiology.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »